Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi), belinostat, is an emerging and novel therapeutic...
Saved in:
Main Authors: | Bodiford A, Talbott MS, Reddy NM |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/7f9b2bb7038a46f3b3e17cfcefd11a9f |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat
by: Zhang CL, et al.
Published: (2012) -
Advances in the diagnosis and management of lymphoma
by: Matasar MJ, et al.
Published: (2012) -
Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
by: McKinney MS, et al.
Published: (2014) -
Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources
by: Moormann AM, et al.
Published: (2014) -
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
by: Farina F, et al.
Published: (2014)